Kilitch Drugs (India) Share Price Today (KILITCH)
TODAY IN ONE LINE
With a market cap of ₹617.25 Cr., it trades at a P/E of 20.92. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Kilitch Drugs (India) flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 26.5% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 29.0% and Profit up 126.0%
- ●High Capital EfficiencyROCE of 15.7% indicating pricing power
- ●High Promoter HoldingPromoters hold 63.8% skin-in-the-game
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Promoter SellingPromoter holding decreased by 5.46% QoQ
- ●Rising Receivables vs SalesReceivables grew 34.2% outpacing sales growth of 28.5%
Latest Kilitch Drugs (India) News
What changed recently?
Recent events, corporate actions, and announcements.
Kilitch Drugs (India) Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Kilitch Drugs (India) Limited, framed against the sector median so the premium or discount is obvious at a glance.
Kilitch Drugs (India) Limited trades at a P/E of 20.92× and P/B of 2.26×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Kilitch Drugs (India) Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Kilitch Drugs (India) Limited — derived from the live tape, not yesterday's close.
Kilitch Drugs (India) Limited last traded at ₹196.99 with an intraday range of ₹194.25–₹207.77 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹196.99| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 232.13 | +35.14 | +17.84% |
| R3 | 218.61 | +21.62 | +10.98% |
| R2 | 213.19 | +16.20 | +8.22% |
| R1 | 205.09 | +8.10 | +4.11% |
| PIVOT | 199.67 | 2.68 | 1.36% |
| CURRENT | 196.99 | — | — |
| S1 | 191.57 | -5.42 | -2.75% |
| S2 | 186.15 | -10.84 | -5.50% |
| S3 | 178.05 | -18.94 | -9.61% |
| S4 | 164.53 | -32.46 | -16.48% |
KILITCH is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹–₹
Trading Inside opening range
Kilitch Drugs (India) Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Kilitch Drugs (India) Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Kilitch Drugs (India) Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹617.25 Cr. and reported EPS of ₹8.92.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 198 | 235 ▲ 18.7% |
| Sales Growth YoY %Derived | 28.47% | 18.74% |
| Other Income | 11 | 11 ▲ 0.7% |
| Total Income | 209 | 247 ▲ 17.8% |
| 105 | 126 ▲ 20.6% | |
| Gross ProfitDerived | 94 | 109 ▲ 16.6% |
| Gross Margin %Derived | 47.27% | 46.43% |
| 62 | 73 ▲ 16.8% | |
| EBITDA (Operating Profit)Derived | 31 | 37 ▲ 16.3% |
| OPM %Derived | 15.87% | 15.54% |
| 8 | 9 ▲ 12.7% | |
| Profit Before Tax (PBT) | 34 | 39 ▲ 12.1% |
| 10 | 9 ▼ 4.0% | |
| Effective Tax %Derived | 27.66% | 23.68% |
| Total Profit for Period | 25 | 30 ▲ 18.3% |
| Less: Non-controlling Interests | -2 | -1 ▲ 62.2% |
| Net Profit (Owner's PAT)Derived | 27 | 30 ▲ 13.0% |
| Net Profit Margin %Derived | 13.46% | 12.81% |
| PAT Growth YoY %Derived | 82.86% | 12.98% |
| Earnings Per Share (EPS ₹) | 7.64 | 8.63 ▲ 13.0% |
| Diluted Shares Outstanding (Cr) | 3 | 3 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -1 | -1 ▲ 6.3% |
| Total Expenses (incl. D&A & Interest) | 175 | 208 ▲ 18.9% |
| Material Cost % of RevenueDerived | 53.32% | 53.11% |
| Employee Cost % of RevenueDerived | 5.71% | 6.08% |
| Other Cost % of RevenueDerived | 25.69% | 24.82% |
| Interest Coverage (x)Derived | 5.62x | 5.93x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 51 | 82 ▲ 61.7% | 53 ▼ 35.4% | 69 ▲ 28.5% | 114 ▲ 66.7% | 140 ▲ 22.2% | 154 ▲ 10.6% | 198 ▲ 28.5% | 235 ▲ 18.7% | |
| Sales Growth YoY %Derived | — | 61.71% | -35.36% | 28.51% | 66.71% | 22.20% | 10.58% | 28.47% | 18.74% | |
| Other Income | 3 | 4 ▲ 39.3% | 4 ▲ 3.0% | 3 ▼ 35.3% | 3 ▲ 9.1% | 3 ▲ 0.3% | 4 ▲ 53.5% | 11 ▲ 149.2% | 11 ▲ 0.7% | |
| Total Income | 54 | 86 ▲ 60.5% | 57 ▼ 33.6% | 71 ▲ 23.9% | 117 ▲ 64.5% | 143 ▲ 21.7% | 159 ▲ 11.5% | 209 ▲ 31.9% | 247 ▲ 17.8% | |
26 | 48 ▲ 85.3% | 29 ▼ 39.6% | 37 ▲ 28.3% | 65 ▲ 75.4% | 75 ▲ 14.3% | 79 ▲ 5.6% | 105 ▲ 32.4% | 126 ▲ 20.6% | ||
| Gross ProfitDerived | 25 | 34 ▲ 37.2% | 24 ▼ 29.4% | 31 ▲ 28.8% | 49 ▲ 56.3% | 65 ▲ 32.9% | 75 ▲ 16.3% | 94 ▲ 24.3% | 109 ▲ 16.6% | |
| Gross Margin %Derived | 49.04% | 41.61% | 45.45% | 45.56% | 42.72% | 46.45% | 48.85% | 47.27% | 46.43% | |
20 | 27 ▲ 38.4% | 24 ▼ 12.0% | 26 ▲ 8.3% | 38 ▲ 47.7% | 47 ▲ 23.0% | 51 ▲ 8.4% | 62 ▲ 21.5% | 73 ▲ 16.8% | ||
| EBITDA (Operating Profit)Derived | 5 | 7 ▲ 32.8% | 0 ▼ 97.2% | 5 ▲ 2540.0% | 10 ▲ 99.7% | 18 ▲ 69.4% | 24 ▲ 37.5% | 31 ▲ 30.3% | 37 ▲ 16.3% | |
| OPM %Derived | 10.35% | 8.50% | 0.37% | 7.58% | 9.08% | 12.58% | 15.65% | 15.87% | 15.54% | |
2 | 2 ▲ 19.0% | 3 ▲ 11.7% | 3 ▲ 0.9% | 4 ▲ 33.7% | 8 ▲ 131.2% | 9 ▲ 9.6% | 8 ▼ 12.2% | 9 ▲ 12.7% | ||
| Profit Before Tax (PBT) | 6 | 9 ▲ 40.5% | 2 ▼ 81.3% | 5 ▲ 218.5% | 10 ▲ 87.8% | 12 ▲ 25.0% | 19 ▲ 61.1% | 34 ▲ 78.1% | 39 ▲ 12.1% | |
1 | 5 ▲ 395.3% | 1 ▼ 83.9% | 1 ▲ 76.8% | 3 ▲ 151.3% | 4 ▲ 9.7% | 6 ▲ 54.9% | 10 ▲ 65.0% | 9 ▼ 4.0% | ||
| Effective Tax %Derived | 15.71% | 55.40% | 47.61% | 26.43% | 35.37% | 31.06% | 29.86% | 27.66% | 23.68% | |
| Total Profit for Period | 5 | 4 ▼ 25.7% | 1 ▼ 78.0% | 4 ▲ 347.3% | 6 ▲ 65.0% | 8 ▲ 33.3% | 14 ▲ 63.9% | 25 ▲ 83.7% | 30 ▲ 18.3% | |
| Less: Non-controlling Interests | — | — | — | 0 | -1 ▼ 1308.0% | -2 ▼ 87.7% | -1 ▲ 52.6% | -2 ▼ 71.6% | -1 ▲ 62.2% | |
| Net Profit (Owner's PAT)Derived | 5 | 4 ▼ 25.7% | 1 ▼ 78.0% | 4 ▲ 336.0% | 7 ▲ 100.7% | 10 ▲ 41.8% | 15 ▲ 39.8% | 27 ▲ 82.9% | 30 ▲ 13.0% | |
| Net Profit Margin %Derived | 10.10% | 4.64% | 1.58% | 5.36% | 6.45% | 7.48% | 9.46% | 13.46% | 12.81% | |
| PAT Growth YoY %Derived | — | -25.67% | -78.01% | 336.00% | 100.68% | 41.82% | 39.75% | 82.86% | 12.98% | |
| Earnings Per Share (EPS ₹) | 1.73 | 1.15 ▼ 33.5% | 0.25 ▼ 78.3% | 1.09 ▲ 336.0% | 2.17 ▲ 99.1% | 3.08 ▲ 41.9% | 4.18 ▲ 35.7% | 7.64 ▲ 82.8% | 8.63 ▲ 13.0% | |
| Diluted Shares Outstanding (Cr) | 3 | 3 ▲ 11.8% | 3 ▲ 0.5% | 3 ▲ 0.4% | 3 ▲ 0.6% | 3 ▲ 0.0% | 3 ▲ 3.2% | 3 ▲ 0.0% | 3 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 1 | -1 ▼ 258.2% | -3 ▼ 194.2% | 5 ▲ 268.2% | 2 ▼ 62.1% | -0 ▼ 116.0% | 6 ▲ 1851.6% | -1 ▼ 120.4% | -1 ▲ 6.3% | |
| Total Expenses (incl. D&A & Interest) | 48 | 78 ▲ 63.1% | 56 ▼ 28.3% | 66 ▲ 18.3% | 108 ▲ 62.7% | 131 ▲ 21.4% | 139 ▲ 6.9% | 175 ▲ 25.5% | 208 ▲ 18.9% | |
| Material Cost % of RevenueDerived | 51.83% | 58.61% | 55.93% | 52.86% | 57.32% | 53.39% | 51.23% | 53.32% | 53.11% | |
| Employee Cost % of RevenueDerived | 8.43% | 6.41% | 10.67% | 7.65% | 5.41% | 8.41% | 6.49% | 5.71% | 6.08% | |
| Other Cost % of RevenueDerived | 30.25% | 26.70% | 34.41% | 30.33% | 28.23% | 25.46% | 26.72% | 25.69% | 24.82% | |
| Interest Coverage (x)Derived | — | 13.09x | -2.52x | 4.25x | 6.60x | 2.85x | 3.51x | 5.62x | 5.93x |
Kilitch Drugs (India) segment analysis : revenue and profit mix.
Disclosed business segments at Kilitch Drugs (India) with their share of revenue and profit, switchable between consolidated and standalone reporting.
Kilitch Drugs (India) discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Kilitch Drugs (India) Limited.
Our AI distills the core fundamental drivers supporting Kilitch Drugs (India) Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Kilitch Drugs (India) Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Low debt-to-equity ratio of 0.32 ensures strong financial flexibility and conservative leverage.
Operating margin of 14.00% and net margin of 12.81% demonstrate solid profitability metrics.
Latest quarterly EPS grew 34.6% YoY with sales up 29%, signaling strong operational momentum.
TTM EPS grew 26.5% YoY, reflecting sustained earnings acceleration and business traction.
Promoter holding at 63.77% signals strong alignment between management and shareholder interests.
Key Risks.
Zero dividend yield offers no income appeal to dividend-seeking investors.
ROE of 12.36% and ROCE of 15.70% lag peer benchmarks, indicating lower capital efficiency.
Free cash flow turned negative in recent quarters, signaling working capital pressures.
Flat price momentum across 13-week, 26-week, and 52-week periods reflects weak investor demand.
Operating cash flow volatile. negative ₹1.19 Cr in 2024, positive ₹15.23 Cr in 2025.
Flip Conditions.
Valuation risk. a P/E above 27 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 32.54. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Kilitch Drugs (India) Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Kilitch Drugs (India) Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Kilitch Drugs (India) Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Kilitch Drugs (India) Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Kilitch Drugs (India) Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Kilitch Drugs (India) Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Kilitch Drugs (India) Limited stood at 59.3% of traded volume, against a 20-day average of 42.6%.
Kilitch Drugs (India) announcements: results, concalls, ratings, M&A.
Filings Kilitch Drugs (India) sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Kilitch Drugs (India) files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 48 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Kilitch Drugs (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Trading Window
Kilitch Drugs (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Commencement of commercial production/operations
Kilitch Drugs (India) Limited has informed the Exchange about Commencement of commercial production/operations
Disclosure under SEBI Takeover Regulations
Kilitch Drugs (India) Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Disclosure under SEBI Takeover Regulations
Mukund mehta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial…
Kilitch Drugs (India) dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Kilitch Drugs (India) has declared, sequenced by announce and record date.
Kilitch Drugs (India) corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Kilitch Drugs (India) Limited: business, sector, key facts.
What Kilitch Drugs (India) Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Kilitch Drugs (India) Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: KILITCH, BSE: 524500.
Kilitch Drugs (India) Limited is a pharmaceutical company based in Mumbai, India, established in 1978. Their core business revolves around the development, manufacturing, and distribution of a wide array of pharmaceutical products within the Indian market and through exports.
A significant portion of their product portfolio consists of parenteral and nasal formulations. This includes medications targeting various therapeutic areas such as gastroenterology, pain management (NSAIDs, anticonvulsants), infectious diseases (antibacterial, antifungal, anti-malarial), cardiovascular health, and more. Specific examples mentioned include iron supplements for anemia treatment, metered nasal drops, and antibiotics like Klavmox and Onecef. They also offer a comprehensive range of vaccines and veterinary products.
Beyond parenterals and nasals, Kilitch Drugs produces a substantial line of oral medications. This includes diverse formulations like tablets, capsules, syrups, and powders catering to various therapeutic needs, including cardiovascular and diabetic conditions. Specific branded products like ROIPAR, DUREGRA, and ROIVIT (effervescent tablets and powders) and CELTINE (nutritional product) highlight the breadth of their offerings.
The company further expands its reach into topical treatments with C-Seal, a skin adhesive used in wound care. Their product line also extends into the cosmetics and herbal sectors. This includes a variety of skincare and haircare products (oils, creams, lotions, etc.), alongside herbal remedies aimed at addressing conditions like sore throats, prostate issues, and supplementing treatments for diabetes, obesity, and libido enhancement.
In summary, Kilitch Drugs (India) Limited operates a diversified pharmaceutical business with a broad product portfolio encompassing parenteral, nasal, and oral medications; topical treatments; cosmetics; and herbal remedies. Their operations include both domestic distribution within India and international exports, reflecting a substantial presence in the Indian pharmaceutical market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Kilitch Drugs (India) Limited (KILITCH).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Kilitch Drugs (India) Limited (KILITCH)?
The current share price of Kilitch Drugs (India) Limited (KILITCH) is ₹196.99. Today, the stock has declined by ₹8.53 (4.15%), trading in a range of ₹194.25 to ₹207.77. The stock opened at ₹206.99 with a trading volume of 1,36,445 shares.
02Is Kilitch Drugs (India) Limited stock a good investment for long-term?
Kilitch Drugs (India) Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹617.25 crores, P/E ratio of 20.92, ROE of 12.36%, and ROCE of 15.70%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Kilitch Drugs (India) Limited stock?
The 52-week high price of Kilitch Drugs (India) Limited (KILITCH) is ₹439, while the 52-week low is ₹117.25. Currently trading at ₹196.99, the stock is 24.8% away from its 52-week low and 55.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Kilitch Drugs (India) Limited stock at the current price?
Whether to buy Kilitch Drugs (India) Limited stock at ₹196.99 depends on multiple factors. The stock is currently trading with a P/E ratio of 20.92 and P/B ratio of 2.26. Today's performance shows a loss of 4.15%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Kilitch Drugs (India) Limited and when is the next dividend?
Kilitch Drugs (India) Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹196.99, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Kilitch Drugs (India) Limited?
Kilitch Drugs (India) Limited's key financial metrics include: P/E Ratio: 20.92, P/B Ratio: 2.26, ROE: 12.36%, ROCE: 15.70%, Dividend Yield: 0.00%, EPS: ₹8.92, Book Value: ₹81.67, and Debt-to-Equity: 32.04. The company's market cap stands at ₹617.25 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Kilitch Drugs (India) Limited stock performing today in the market?
Kilitch Drugs (India) Limited stock opened at ₹206.99 and is currently trading at ₹196.99, showing a decline of ₹8.53 (4.15%). The intraday high is ₹207.77 and low is ₹194.25. The trading volume stands at 1,36,445 shares, indicating moderate market participation today.
08What is the P/E ratio of Kilitch Drugs (India) Limited and what does it indicate?
Kilitch Drugs (India) Limited has a Price-to-Earnings (P/E) ratio of 20.92, which means investors are willing to pay ₹20.92 for every ₹1 of earnings. With an EPS of ₹8.92, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Kilitch Drugs (India) Limited (KILITCH) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.